View Older Stories View More Recent Stories

Mar 26, 2018 08:00AM Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 20, 2018 12:50PM Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
Mar 20, 2018 12:48PM Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
Mar 15, 2018 08:04AM Seattle Genetics (SGEN) Names Dr. Alpna Seth to Board
Mar 15, 2018 08:00AM Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors
Mar 13, 2018 08:00AM Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
Mar 9, 2018 09:28AM Seattle Genetics (SGEN) Completes Acquisition of Cascadian Therapeutics (CASC)
Mar 9, 2018 09:26AM Seattle Genetics Completes Acquisition of Cascadian Therapeutics
Mar 9, 2018 06:00AM Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics
Mar 7, 2018 08:03AM Seattle Genetics (SGEN) Initiates New Phase 1 Study in R/R Multiple Myeloma
Mar 7, 2018 08:00AM Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Feb 27, 2018 08:00AM Seattle Genetics to Present at Cowen and Company 38th Annual Health Care Conference
Feb 16, 2018 08:12AM Seattle Genetics (SGEN) Announces Expiration of HSR Waiting Period for Acquisition of Cascadian (CASC)
Feb 16, 2018 08:00AM Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period
Feb 9, 2018 06:45AM Seattle Genetics (SGEN), Pieris Pharmaceuticals (PIRS) Announce Multi-Program Immuno-Oncology Pact
Feb 9, 2018 06:45AM Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
Feb 9, 2018 06:45AM Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
Feb 8, 2018 05:43PM Seattle Genetics (SGEN) Commences Tender Offer for Cascadian Therapeutics (CASC)
Feb 8, 2018 05:39PM Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.
Feb 6, 2018 04:02PM Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
Jan 31, 2018 06:31AM Seattle Genetics (SGEN) to Acquire Cascadian Therapeutics (CASC) for $10/Share
Jan 31, 2018 06:30AM Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
Jan 22, 2018 08:13AM Seattle Genetics (SGEN) Announces ADCETRIS Receives EC Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Jan 22, 2018 08:00AM Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Jan 18, 2018 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
Jan 8, 2018 08:00AM Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference
Jan 2, 2018 08:01AM Seattle Genetics (SGEN) Grantred FDA Supplemental Biologics License Application and Grants Priority Review for ADCETRIS (Brentuximab Vedotin)
Jan 2, 2018 08:00AM FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
Dec 19, 2017 08:00AM Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
Dec 11, 2017 10:31AM Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY) Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS and Opdivo in R/R Hodgkin Lymphoma
Dec 11, 2017 10:30AM Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refracto
Dec 11, 2017 05:50AM Seattle Genetics (SGEN) Reports Five-Year Survival Results from Phase 1 Trial of ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma
Dec 11, 2017 05:45AM Seattle Genetics (SGEN) and Takeda Highlight Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Dec 11, 2017 05:39AM Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma
Dec 10, 2017 09:00AM Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting
Dec 10, 2017 08:00AM Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Dec 10, 2017 08:00AM Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Dec 9, 2017 09:00AM Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual Meeting
Dec 7, 2017 08:01AM Seattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A)
Dec 7, 2017 08:00AM Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium
Dec 4, 2017 08:00AM Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
Nov 9, 2017 12:41PM Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS
Nov 9, 2017 12:40PM Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
Nov 8, 2017 08:00AM Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
Nov 8, 2017 08:00AM Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
Nov 2, 2017 08:19AM Seattle Genetics (SGEN) Submits sBLA to FDA for ADCETRIS in Frontline Advanced Hodgkin Lymphoma
Nov 2, 2017 08:00AM Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
Nov 1, 2017 09:12AM Seattle Genetics (SGEN) to Present Data from Broad ADCETRIS Program at ASH
Nov 1, 2017 09:00AM Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017
Oct 26, 2017 04:02PM Seattle Genetics Reports Third Quarter 2017 Financial Results
View More Recent Stories View Older Stories